UPDATES IN MEDICINE

2021-10-08 16:50:01 ​​ Myocarditis after mRNA COVID 19 Vaccine


● Myocarditis after Pfizer (BNT162b2) Vaccine in Israel

In an Israeli Ministry of Health database, 136 definite or probable cases of myocarditis were detected among 5 million vaccinated persons. The rate ratio after two doses as compared with unvaccinated persons was 2.35, with the highest risk among male recipients between the ages of 16 and 19 years.


● Myocarditis after Pfizer Vaccination in a Large Health Care Organization

Among 2.5 million patients who received the BNT162b2 mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons, with the highest incidence (10.69 per 100,000 persons) among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-10-07 16:30:00 ​​WANING COVID -19 VACCINE PROTECTION

● In Israel
In a longitudinal study involving nearly 4000 health care workers in Israel who had received two doses of BNT162b2 vaccine, levels of spike-binding IgG and neutralizing antibody decreased and did so to a greater extent in men, persons 65 years of age or older, and persons with immunosuppression. Obese persons had higher levels of antibody than nonobese persons.

● In Qatar
In a test-negative, case–control study involving more than 900,000 participants in Qatar, vaccine effectiveness peaked at 77.5% in the first month after the second dose. The effectiveness fell thereafter to as low as 20% in months 5 through 7 after vaccination, but protection against serious Covid-19 remained greater than 90% for at least 6 months.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-10-06 16:45:00 ​​​​​​ Effectiveness of Pfizer vaccine up to 6 months

• Interpretation - Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection.


Join @Updates_in_Medicine Open / Comment

2021-10-06 06:38:59 Hello guys...
Here you can join our latest channel
@Medical_Quiz_Channel

There we will be posting Medical Questions and answers with explanation Daily.

This channel is great for people who are preparing for Exams. If not, frequent refreshing of your knowledge will make you a better doctor. Open / Comment

2021-10-05 17:00:03 ​​ American scientists David Julius and Ardem Patapoutian win Medicine Nobel for work on heat and touch

American scientists David Julius and Ardem Patapoutian won the 2021 Nobel Prize for Medicine on Monday for the discovery of receptors in the skin that sense temperature and touch and could pave the way for new pain-killers.

Their work, carried out independently, has helped show how humans convert the physical impact from heat or touch into nerve impulses that allow us to "perceive and adapt to the world around us," the Nobel Assembly at Sweden's Karolinska Institute said.


Join @Updates_in_Medicine Open / Comment

2021-10-04 16:28:55 ​​ First Effective Oral Antiviral Drug Against COVID - MOLNUPIRAVIR

Merck and Ridgeback’s Investigational Oral Antiviral MOLNUPIRAVIR Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study, according to a media report by the pharmaceutical company

At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died. No deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. 

We are still awaiting publication of this study in a proper scientific journal.


Join @Updates_in_Medicine Open / Comment

2021-10-02 15:44:45 ​​ Intensive Blood-Pressure Control in Older Patients

In 8511 Chinese patients 60 to 80 years of age with hypertension, intensive treatment (systolic blood-pressure target, 110 to <130 mm Hg) resulted in a lower incidence of cardiovascular events than standard treatment (target, 130 to <150 mm Hg). The two groups had similar incidences of adverse events, except for hypotension, which occurred more frequently with intensive treatment.


Join @Updates_in_Medicine Open / Comment

2021-10-01 05:01:33 ​ Antidepressants in Primary Care Practice

In a trial in the United Kingdom, patients with depression who were being treated in primary care practices and who felt well enough to discontinue antidepressant therapy were randomly assigned to maintain their current antidepressant therapy or to discontinue such therapy. By 1 year, relapse had occurred in 39% of patients in the maintenance group and in 56% in the discontinuation group.


Join @The_NEJM Open / Comment

2021-09-30 04:36:19 COVID Antibody treatment in Early Disease for high risk Outpatients

This phase 3, placebo-controlled platform trial evaluated a single infusion of casirivimab and imdevimab (REGEN-COV) at 2400-mg and 1200-mg doses in outpatients with acute SARS-CoV-2 infection. The incidence of Covid-19–related hospitalization was lower and recovery was faster among patients who received the antibody combination than among those who received placebo.


Join @Updates_in_Medicine Open / Comment

2021-09-30 04:27:49 @Updates_in_Medicine Open / Comment